首页> 外文期刊>The British journal of general practice: the journal of the Royal College of General Practitioners >Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessment.
【24h】

Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessment.

机译:检测适合药物治疗的阿尔茨海默氏病患者:三种评估方法的比较。

获取原文
           

摘要

BACKGROUND. Therapy to enhance cholinergic function in the brain is under evaluation for the treatment of Alzheimer's disease. Tetrahydroaminoacridine (tacrine) has recently received a product licence in the United States of America for the treatment of Alzheimer's disease, and the licence application in the United Kingdom will shortly be reviewed. It is therefore possible that this drug will become available for use in the UK in due course. There will then be a need for screening procedures for a large number of elderly patients to decide whether or not they have dementia and, if so, whether it is the result of Alzheimer's disease and is suitable for treatment with the new drug. METHOD. A total of 246 patients aged 75 years or over in two general practices in Bristol were assessed to investigate the potential workload such screening would engender. Three different assessment schedules for the diagnosis of dementia were compared--the mini-mental state examination, the Kew test, and the abbreviated mental test score. RESULTS. None of the assessment schedules was found to be particularly onerous, with median times for administration of five, three and two minutes, respectively. A score of 23 or less on the mini-mental state examination was taken as the main cut-off point for further evaluation. Sixty six patients obtained this score--in 25 the low score reflected factors other than dementia, and 11 others declined further assessment. Of the remaining 30 patients only four had probable Alzheimer's disease at an appropriate level of severity for treatment, and lived with a carer who could ensure compliance and monitor side effects. Two of these patients were receiving conflicting medical treatment and a third declined therapy, leaving only one person for whom treatment could be prescribed. CONCLUSION. It seems likely that of those medically suitable for treatment, it may not be possible to prescribe tacrine for an appreciable proportion. Nevertheless, all potential patients should be screened as the procedures involved are not onerous and at least some of those found suitable for treatment are likely to benefit from this new approach.
机译:背景。目前正在评估增强大脑胆碱能功能的疗法,以治疗阿尔茨海默氏病。四氢氨基ac啶(他克林)最近在美利坚合众国获得了用于治疗阿尔茨海默氏病的产品许可证,不久将在英国审查该许可证的申请。因此,这种药物有可能在适当时候在英国使用。然后,将需要针对大量老年患者的筛查程序,以决定他们是否患有痴呆症,如果是,则判断是否是阿尔茨海默氏病的结果并且适合用新药治疗。方法。在布里斯托尔的两种常规实践中,对总共246名年龄在75岁或以上的患者进行了评估,以调查这种筛查可能产生的潜在工作量。比较了三种不同的痴呆症诊断评估时间表-迷你精神状态检查,Kew测验和简短的心理测验分数。结果。没有一个评估时间表特别繁琐,管理时间分别为五分钟,三分钟和两分钟。迷你精神状态检查的得分不超过23分作为进一步评估的主要起点。 66位患者获得了该评分-在25位低评分中反映了痴呆以外的因素,另有11位患者拒绝进一步评估。在其余的30名患者中,只有4名在适当的严重程度下可能患有阿尔茨海默氏病,并且与能够确保依从性和监测副作用的护理人员一起生活。这些患者中有两个正在接受相互矛盾的药物治疗,而第三个患者则拒绝接受治疗,仅剩下一名可以接受治疗的人。结论。在那些医学上适合治疗的人看来,不可能将他克林开出可观的比例。然而,应对所有潜在患者进行筛查,因为所涉及的过程并不繁重,并且至少一些适合治疗的患者可能会从这种新方法中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号